BioCentury | Apr 25, 2019
Finance

The academic founders' conundrum

First-time academic entrepreneurs face a circular problem: while they’re continually sought after by VCs and pharmas seeking the next “big thing”, they also face an arduous path to establish their bona fides - not for their...
BioCentury | Sep 29, 2017
Strategy

Bridge to innovation

...into innovation,” he said. “To implement this strategy, Qilu really looked at where is the hotbed...
...immuno-oncology biologics. “Boston has distanced itself from the rest of the pack for being the hotbed...
BioCentury | Mar 31, 2017
Politics, Policy & Law

Gottlieb’s job one

...build new regulatory thinking into its DNA. To succeed, Gottlieb will have to create this hotbed...
BioCentury | Jun 30, 2016
Strategy

Open house at NIBR

Since stepping into his new role in March as president of Novartis Institutes for BioMedical Research (NIBR), the research arm of Novartis AG , James "Jay" Bradner has been busy making plans to experiment with open...
BioCentury | Mar 24, 2014
Strategy

A Remembrance: The quintessential serial entrepreneur

Very few of us will live as long, invent as much, or improve as many lives as Alejandro Zaffaroni. Alex, who was 91 when he passed away this month, already was an eminence grise in...
BioCentury | Feb 20, 2012
Strategy

Externalizing neurology

AstraZeneca plc is betting that significantly downsizing internal R&D in neurology will allow it to run cheaper and faster - and if necessary fail more quickly and cost-effectively - in a disease area that has historically high...
BioCentury | May 27, 2006
Financial News

Sphere raises L6.2M

...investors Oxford Capital; Fritas; and Schroders Investment Management joined existing investors Artemis ; Herald Ventures; Hotbed...
BioCentury | Feb 14, 2000
Finance

The head-turning allure of the market

OXFORD - Europe will end up with about 100 companies and 60 of those will be British. That was the bold prediction of Chris Evans, one of Britain's most outspoken biotech entrepreneurs and founder of Merlin...
BioCentury | Nov 3, 1997
Finance

Biotech hotbed in Copenhagen

OXFORD - Copenhagen looks poised to become the focus of European IPO activity in 1998. The post-IPO track record of NeuroSearch A/S in the past 15 months - which has seen the value of NEUS rise threefold...
Items per page:
1 - 9 of 9
BioCentury | Apr 25, 2019
Finance

The academic founders' conundrum

First-time academic entrepreneurs face a circular problem: while they’re continually sought after by VCs and pharmas seeking the next “big thing”, they also face an arduous path to establish their bona fides - not for their...
BioCentury | Sep 29, 2017
Strategy

Bridge to innovation

...into innovation,” he said. “To implement this strategy, Qilu really looked at where is the hotbed...
...immuno-oncology biologics. “Boston has distanced itself from the rest of the pack for being the hotbed...
BioCentury | Mar 31, 2017
Politics, Policy & Law

Gottlieb’s job one

...build new regulatory thinking into its DNA. To succeed, Gottlieb will have to create this hotbed...
BioCentury | Jun 30, 2016
Strategy

Open house at NIBR

Since stepping into his new role in March as president of Novartis Institutes for BioMedical Research (NIBR), the research arm of Novartis AG , James "Jay" Bradner has been busy making plans to experiment with open...
BioCentury | Mar 24, 2014
Strategy

A Remembrance: The quintessential serial entrepreneur

Very few of us will live as long, invent as much, or improve as many lives as Alejandro Zaffaroni. Alex, who was 91 when he passed away this month, already was an eminence grise in...
BioCentury | Feb 20, 2012
Strategy

Externalizing neurology

AstraZeneca plc is betting that significantly downsizing internal R&D in neurology will allow it to run cheaper and faster - and if necessary fail more quickly and cost-effectively - in a disease area that has historically high...
BioCentury | May 27, 2006
Financial News

Sphere raises L6.2M

...investors Oxford Capital; Fritas; and Schroders Investment Management joined existing investors Artemis ; Herald Ventures; Hotbed...
BioCentury | Feb 14, 2000
Finance

The head-turning allure of the market

OXFORD - Europe will end up with about 100 companies and 60 of those will be British. That was the bold prediction of Chris Evans, one of Britain's most outspoken biotech entrepreneurs and founder of Merlin...
BioCentury | Nov 3, 1997
Finance

Biotech hotbed in Copenhagen

OXFORD - Copenhagen looks poised to become the focus of European IPO activity in 1998. The post-IPO track record of NeuroSearch A/S in the past 15 months - which has seen the value of NEUS rise threefold...
Items per page:
1 - 9 of 9